drugset / Trial / NCT07617376

Pre-discharge Influenza Vaccination in Patients Hospitalized for Acute Cardiac Conditions

NCT07617376

Phase 4 Recruiting 400 enrolled Wroclaw Medical University
RandomizedParallel-groupOpen-labelPrevention

Summary

Patients hospitalized for acute cardiac conditions-including acute myocardial infarction, acute heart failure, pulmonary embolism, arrhythmias, and hypertensive emergencies-represent a heterogeneous population at very high risk of recurrent cardiovascular events. Influenza infection may act as a trigger for adverse cardiovascular events. Given the persistently low influenza vaccination uptake despite evidence-based benefits observed in vulnerable populations, including patients with cardiac conditions, new strategies to improve vaccination coverage are being explored. Recently, increasing attention has been directed toward an approach already used in fields such as neonatology, where vaccinations are administered prior to hospital discharge. In this investigator-initiated, single-center, randomized, open-label interventional study, we will evaluate whether influenza vaccination administered within 24 hours before hospital discharge in patients hospitalized for acute cardiac conditions is safe and effective in reducing subsequent infections, cardiovascular events, and mortality during the 6 months following hospitalization.

Timeline

Start
2025-11-12
Primary completion
2026-12-31
Completion
2027-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Influenza Virus Vaccine Vaccine